AstraZeneca PLC (AZN)vsBiogen Inc (BIIB)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
BIIB
Biogen Inc
$195.34
-0.57%
HEALTHCARE · Cap: $29.53B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 508% more annual revenue ($60.44B vs $9.94B). AZN leads profitability with a 17.2% profit margin vs 13.8%. AZN appears more attractively valued with a PEG of 1.39. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BIIB
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+37.9%
Fair Value
$308.06
Current Price
$195.34
$112.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Earnings expanding 31.1% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
1.9% revenue growth
ROE of 7.4% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : BIIB
The strongest argument for BIIB centers on Price/Book, Operating Margin, EPS Growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : BIIB
The primary concerns for BIIB are Revenue Growth, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while BIIB is a value play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 63/100), backed by strong 17.2% margins and 12.5% revenue growth. BIIB offers better value entry with a 37.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Biogen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?